Given that CBD and GS967 preferentially target resurgent and persistent currents over transient currents in Nav1.2, these compounds could prove to be more effective AEDs than standard treatments such as phenytoin for patients with epilepsies presumably caused by SCN2A mutations that enhance one or both of these currents, such as the A263V or R1882Q mutations. The gene discussed is SCN2A; the disease is epilepsy.